KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Tax Provisions (2016 - 2026)

Bristol Myers Squibb has reported Tax Provisions over the past 18 years, most recently at $561.0 million for Q1 2026.

  • Quarterly Tax Provisions rose 10.22% to $561.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Mar 2026, up 246.35% year-over-year, with the annual reading at $2.3 billion for FY2025, 310.11% up from the prior year.
  • Tax Provisions was $561.0 million for Q1 2026 at Bristol Myers Squibb, up from $384.0 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $919.0 million in Q3 2025 and troughed at -$398.0 million in Q2 2024.
  • The 5-year median for Tax Provisions is $404.0 million (2022), against an average of $303.2 million.
  • Year-over-year, Tax Provisions tumbled 141.21% in 2023 and then surged 287.88% in 2025.
  • A 5-year view of Tax Provisions shows it stood at -$166.0 million in 2022, then surged by 46.99% to -$88.0 million in 2023, then surged by 212.5% to $99.0 million in 2024, then surged by 287.88% to $384.0 million in 2025, then soared by 46.09% to $561.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Tax Provisions are $561.0 million (Q1 2026), $384.0 million (Q4 2025), and $919.0 million (Q3 2025).